Stimulation of PMN with inflammatory mediators markedly augments Fc and CR1 receptor-mediated ingestion. However, CDM1/CD18-deficient PMN from three patients with complete leukocyte adhesion deficiency (LAD) failed to recruit phagocytic function in response to phorbol esters, cytokine, or ArgGly-Asp-containing ligand stimulation. Because stimulated ingestion is protein kinase C (PKC)-dependent, our data indicate that LAD PMN exhibit only PKC-independent phagocytosis.
Introduction
Phagocytosis is a complex biological process ofspecialized cells which is essential for normal host defense. It is necessary not only for the uptake and destruction of pathogens but also for the clearance of immune complexes, removal of damaged tissue, and initiation of wound repair. Despite its central role in host defense, knowledge of the regulation of phagocytic function at inflammatory sites has lagged behind understanding of activation of the respiratory burst and exocytosis, other func-tions of professional phagocytes required for the maintenance of homeostasis. Recent investigations from our group into the regulation of human neutrophil (PMN) phagocytosis have led us to hypothesize that phagocytosis by PMN is primarily a recruited function at inflammatory sites (1) (2) (3) (4) (5) . Stimulation of PMN with various inflammatory mediators markedly augments both Fc-and CR1-mediated ingestion (1) (2) (3) (4) (5) (6) (7) (8) (9) . This recruitment of phagocytic function is reflected not only in the total number of ingested targets but also in the percentage of PMN participating in the phagocytic process (1, 2) . Presumably, this regulation of ingestion acts to limit the damaging products of PMN activation, such as toxic oxygen metabolites and secreted lysosomal products, to the site of inflammation.
We and others have found that PMN can recruit several distinct molecular mechanisms for phagocytosis in response to inflammatory signals, which may be regulated further by the specific opsonin (IgG, C4b, C3b, and C3bi) and opsonin receptor (FcRII, FcRIII, CR1, and CR3) engaged (1) (2) (3) (4) (5) (6) (7) (8) (9) . In addition, monocytes and macrophages employ quite different molecular mechanisms for phagocytosis from those employed by PMN, even when the same opsonin or opsonin receptor is involved (1, 10) . In this manner, at inflammatory sites where PMN and macrophages encounter pro-inflammatory cytokines, interferons, interleukins, chemotactic peptides, and components of the extracellular matrix, ingestion is not only augmented, but the molecular mechanism involved in phagocytosis may be altered. As an example, we have shown recently that ingestion of IgG-opsonized targets by nonstimulated PMN is not dependent upon protein kinase C (PKC)' activation. However, when PMN are stimulated with tumor necrosis factor-a (TNF-a), not only is ingestion of the IgG-opsonized targets markedly increased, but PKC translocation is also greatly augmented over the minimal amount observed with either IgG or TNF-a alone (11) . This synergism in activation of PKC is essential for the increased ingestion by PMN exposed to TNF-a (11) . The importance ofthese data to host defense is demonstrated by the fact that PMN from patients with chronic granulomatous disease (CGD), which lack the ability to generate a respiratory burst, as well as PMN from patients with paroxysmal nocturnal hemoglobinuria, which lack expression of FcRIII, fail to amplify ingestion ofIgG-opsonized targets in response to cytokine (TNF-a) stimulation (4, 12) . Therefore, defects in the different molecular mechanisms for phagocytosis employed by PMN at inflammatory sites may be observed in both genetic and acquired disorders which exhibit a predisposition to serious and recurrent infection. In this regard, the purpose of the present work is to determine whether CDl 1/CD 1 8-deficient PMN from three patients with complete leukocyte adhesion deficiency (LAD) (13) would be capable of recruiting the ingestion mechanisms expected to predominate at inflammatory foci. These patients lack the expression of a family of adhesion molecules (CDI la,b,c/CD1 8) owing to deficient production or maturation ofthe common ,3 chain ofthese heterodimers (13). In vivo, this defect results in a predisposition to severe recurrent bacterial infections (14) . The PMN from patients with LAD are thought to exhibit normal phagocytic function in the absence of stimulation, as long as the target is opsonized with a ligand for a receptor other than CDl lb/CD 18, (e.g., IgG) (14) . However, we and others have shown previously that some monoclonal antibodies (MAbs) to either CDl lb (Mo 1) or to CD1 8 (I1B4) inhibit both stimulated and nonstimulated ingestion of targets opsonized with non-CD 1 lb/CDl 8 ligands (15) (16) (17) . We have interpreted these data to mean that CDl lb/CD 1 8 plays a role in the regulation of both stimulated and nonstimulated phagocytosis independent of its ligand-binding function. The purpose ofthe present work is to resolve this apparent discrepancy.
One possibility to reconcile these data is that the antibodies to CDl lb/CD 1 8 that inhibit ingestion do so by generating an intracellular signal which is inhibitory for ingestion. Alternatively, the patients' PMN may have compensatory mechanisms of ingestion that are in fact different from the mechanisms used by normal PMN. Our extensive investigations into the phagocytic mechanisms employed by normal PMN afforded us the opportunity to assess ifthe same mechanisms are used by LAD PMN. In the present work, we show that PMN from patients with LAD fail to amplify ingestion for either IgGor C4b-opsonized targets in response to stimulation by phorbol esters, cytokines, or Arg-Gly-Asp (RGD)-containing adhesive proteins. Whereas LAD PMN are defective in the mechanism for stimulated ingestion, our data indicate that they do possess and use the mechanism of unstimulated IgG-dependent ingestion used by normal PMN. In addition, our data indicate that the monoclonal antibodies to CDl lb, OKM 1, and OKM10 do not inhibit unstimulated ingestion but do inhibit stimulated ingestion. In this manner, treatment of normal PMN with these antibodies to CD l I b results in reproduction of the LAD phenotype for phagocytic function. In order to explain why antibodies Mo I and 1B4 inhibit a CD I l/CDl 8-independent mechanism ofphagocytosis, we investigated their effects on the intracellular levels of cyclic adenosine monophosphate (cAMP). We had shown previously that agents that increase intracellular cAMP inhibit unstimulated but not stimulated ingestion (3) . We present data which indicate that Mol and 1 B4, but not control antibodies, augment the accumulation of cAMP in response to either immune complex or N-formylmethionyl-leucyl-phenylalanine (FMLP) stimulation. In addition, the ability of these antibodies to inhibit unstimulated ingestion but not stimulated ingestion is abrogated by the inclusion of HA 1004, a putative protein kinase A (PKA) inhibitor. Thus, in the presence of a PKA inhibitor, Mol and 1B4 can also reproduce the LAD phenotype for phagocytic function.
These data indicate that at inflammatory sites, augmentation of PMN phagocytic function is absolutely dependent on the CDl lb/CD 1 8 complex. Because we believe that the mechanism for stimulated ingestion is essential for normal host defense, this suggests that the susceptibility to infection in patients with LAD may be related in part to a failure to enhance ingestion in response to inflammatory stimuli. This may be particularly important at sites, such as the lung, where CDl 1/ CD18-deficient PMN ingress in response to inflammation is relatively normal. Finally, our data demonstrate that both CDl lb/CD18-independent and -dependent mechanisms of phagocytosis exist in PMN. The ability of antibodies Mol and IB4 to inhibit the CDl1 /CD 1 8-independent mechanism of ingestion may be explained by their ability to augment increases in intracellular cAMP in response to stimulation. This suggests that other effects of some antibodies and potential ligands for the CDI lb/CD 1 8 complex may result from alterations in cellular cAMP metabolism.
Methods
Special reagents. The following reagents were purchased from Sigma Chemical Co., St. Louis, MO: phorbol dibutyrate (PDBu), phorbol myristate acetate (PMA), FMLP, isobutylmethylxanthine (IBMX), catalase (bovine liver, 52,000 U/mg), superoxide dismutase (bovine erythrocytes, 3,000 U/mg), cytochrome c (type VI, horse heart), and dibutyrl cAMP (DiBcAMP). PDBu (1 mg/ml), phorbol myristate acetate (PMA, 1 mg/ml), FMLP (22.9 mM), and IBMX (80 mM) were prepared as stock solutions in (DMSO, Aldrich Chemical Co., Milwaukee, WI), were stored at -70°C, and were diluted into aqueous medium immediately before use. Equivalent concentrations of vehicle were used to control for solvent effects. Chicken egg albumin (ovalbumin) and human vitronectin (Vn) were purchased from CalbiochemBehring Corp., La Jolla, CA. The isoquinolinesulfonamide derivatives H7 and HA 1004 were purchased from Seikagaku America, St. Petersburg, FL. They were reconstituted (10 mM) with phosphate-buffered saline and stored protected from light at 4°C. A 10-fold concentrated stock of Hanks' balanced salt solution (HBSS) was purchased from Gibco Laboratories, Grand Island, NY. Human fibronectin (Fn) was purified as described (18) . The synthetic peptide GRGDSC was prepared by the Protein Chemistry Facility, Washington University School ofMedicine. GRGDSC and C as a control were linked to pigeon heart cytochrome c as described (5).
MAbs. Purified MAb to CDl lb/CDI 8 were obtained as follows: OKM1 and OKM10 (anti-CD1 Ib) were the generous gifts ofDr. Patricia Rao, the R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ; Mo-I (IgG2a anti-CDlIb) and IB4 (IgG2a anti-CD 18) as described (17) , Leu-15 (IgG2a anti-CDlIb) from Becton, Dickinson & Co., San Jose, CA; and isotype controls 4B2 (IgG2b) and lB5 (IgG2a) as described (2) . 4B2 and lB5 recognize unknown antigens expressed on PMN. Purified murine monoclonal anti-FcRI (32.2), anti-FcRII (IV.3), and anti-FcRIII (3G8) were purchased from Medarex, Inc., West Lebanon, NH. Anti-CR 1 (3D9) was obtained as described (7).
Isolation ofPMN. PMN were isolated as described (3) from normal volunteers, three patients with LAD followed at the Baylor College of Medicine (14) , and two patients with CGD followed at the University of Missouri-Columbia School of Medicine. Patient samples were obtained when patients were free from infection. LAD patient blood samples were always accompanied by blood drawn at the same time from a normal control. The PMN from these normal volunteers served to control for any effects of transportation on PMN function. Multiple studies of the normal transported PMN showed that their phagocytic, respiratory burst, and excretory responses were not different from PMN isolated from normal volunteers from the laboratory. The LAD patients have been studied previously (14) EIgGhi)-and C4b (EC4b)-opsonized E were prepared as described (3, 19) .
Phagocytosis assays. PMN phagocytosis was assessed by a fluidphase assay as described (1) (2) (3) (4) (5) . The reaction mixtures are described in the figure legends. Phagocytosis was assessed by light microscopy and quantitated as a phagocytic index (PI), the number of E ingested/ 100 PMN.
Superoxide anion assay. Superoxide anion was quantitated by cytochrome c reduction as described (4) Ingestion by LAD PMN is PKC-independent. Our previous studies on the molecular mechanisms of IgG-mediated ingestion by non-stimulated and stimulated PMN have led us to hypothesize that ingestion by buffer-treated PMN is independent of PKC activation. In contrast, PMN stimulated with TNF-a, granulocyte/macrophage colony-stimulating factor (GM-CSF), or PDBu exhibit ingestion ofEIgG which is dependent upon PKC activation (11 is more specific at this concentration for PKA. In contrast, PDBu-and cc-RGDS-stimulated ingestion were completely abrogated by H7 whereas the control HA 1004 had no effect (Fig. 3 A) . In addition, ingestion of EC4b by PDBu-stimulated normal PMN was inhibited 78.3% by H7 and was unaffected by HA 1004 (data not shown). The inclusion of DiBcAMP inhibited IgG-dependent ingestion by normal PMN, but had no effect on EIgG ingestion stimulated by PDBu or cytokines (Fig.  3 A) . This inhibition occurs presumably by activation of PKA and can be overcome by PDBu or cytokine stimulation ofnormal PMN (Fig. 3 A and references 3 and 11). Importantly, ingestion of EIgG by buffer-treated LAD PMN was not inhibited by the inclusion ofeither H7 or HA 1004 (Fig. 3 B) . Fig. 4 , LAD PMN lost PKC activity from cytosolic fractions similarly to normal PMN in response to stimulation with increasing concentrations of PMA.
Because the LAD PMN could translocate PKC normally, we investigated superoxide anion generation, another cell function thought to be dependent upon PKC activation, to determine whether LAD PMN were defective in all PKC-dependent processes. Several reports examining the generation of superoxide anion by LAD PMN have shown that these cells generate superoxide anion after stimulation with high concentrations of either phorbol esters or FMLP (14) . These studies were performed on cells in suspension. However, there has been at least one report of a patient whose PMN in suspension produced elevated levels of superoxide anion as compared to normal PMN in response to FMLP and a reduced response to phorbol ester stimulation (22) . In addition, some forms of adherencedependent activation of the respiratory burst appear to be diminished in these patients (23, 24 previously that both MAb IB4 and Mo 1 inhibit both unstimulated and stimulated ingestion (17) . Therefore, they inhibit both PKC-dependent and -independent ingestion. As shown in Fig. 6 , PMN treated with OKM 1, a MAb to CDl lb, exhibited normal levels of PKC-independent ingestion but failed to respond to either PDBu or Fn to stimulate ingestion, either in the presence or absence of catalase (Fig. 6 B) HA 1004, to reverse IB4-mediated inhibition ofEIgG ingestion by buffer-treated PMN. As we have shown previously and in this paper (Fig. 3) , activation of PKA by DiBcAMP inhibits PKC-independent ingestion of EIgG. Therefore, we reasoned that MAb IB4 might inhibit ingestion by a similar mechanism. As shown in Fig. 7 (Fig. 7 B) yet IB4 inhibition of PDBu-stimulated ingestion with PI in the same range was unaffected by PKA inhibition (Fig. 8 ).
These data indicate that MAbs Mo 1 and IB4 inhibit PKC-dependent ingestion by a completely different mechanism than the mechanism by which they inhibit PKC-independent ingestion of EIgG. Therefore, in the presence of HA 1004, IB4 and Mo 1, as well as OKM 1 and OKM 10 convert normal PMN into the phenotype of LAD PMN for phagocytosis.
These data strongly imply that some antibodies against CDl lb/CD 1 ,ug/ 1.0 x 105 PMN), did not cause a statistically significant increase in intracellular cAMP levels as compared to stimulation with Leu 1 5. In all experiments, cAMP levels of untreated PMN were not significantly different from Leul 5-treated PMN. In contrast to incubation in buffer, stimulation with IgG-containing immune complexes (which mimics stimulation by EIgG) resulted in a statistically significant increase in net picomoles cAMP for the Mo 1-as compared to the Leu 1 5-treated PMN (Fig. 9 ). In addition, we assessed the effect ofMol on FMLP-stimulated cAMP accumulation. FMLP was examined because it is known to increase surface Mac-1 by up-regulation of intracellular pools of CD1 lb/CD 1 8. In addition, the effect of FMLP on intracellular levels of cAMP in PMN has been extensively studied (26) . FMLP does not stimulate adenylate cyclase directly, but does cause a modest increase in cAMP (-net 10 pmol/107 PMN) presumably by inhibition of the cAMP phosphodiesterase (26) . As shown in Fig. 9 , Mol treatment doubled the increment in-cAMP accumulatioo as compared to Leul 5 treatment of FMLP-stimulated PMN. OKM 10 treatment of PMN, which has no effect on unstimulated ingestion, was identical to Leul 5 in its effect on cAMP levels (data not shown). In addition to Mol, 1B4 treatment of PMN as compared to isotype control antibody significantly augmented cAMP levels in response to FMLP stimulation (25.8±4.2 net pmol cAMP/10' PMN with 1B4 as compared to 12.1±5.5 net pmol cAMP with control antibody, P < 0.01). These experiments were performed on PMN treated with IBMX to inhibit the phosphodiesterase which breaks down cAMP. In previous studies with FMLP, the use of IBMX resulted in an increased sensitivity for the detection of cAMP when examined over time (26) . However, in the absence of IBMX, significant increases in cAMP could be detected at earlier time points (26) . (14) , LAD PMN bind EIgG normally and ingest equivalent amounts as normal PMN in the absence of stimulation. However, LAD PMN were completely unresponsive to stimulation with phorbol esters, cytokines, or RGD-containing adhesive proteins (Figs. 1 and 2 ). This defect was demonstrable for both IgG and C4b opsonins. Thus LAD PMN lacked the ability to respond to inflammatory stimuli to amplify phagocytic function and would be expected to exhibit a marked phagocytic defect at inflammatory sites in vivo.
We examined several alternative hypotheses to explain this defect in LAD PMN phagocytic function. An important concern was that the failure to stimulate ingestion was a result not ofthe basic genetic defect but secondary to the chronic or recurrent infections which occur in this disease. If the PMN were activated by inflammatory stimuli in vivo, the signals for stimulating ingestion might already have been encountered and the resultant ingestion by unstimulated LAD PMN would use molecular mechanisms similar to in vitro activated normal PMN. Alternatively, the circulating PMN might represent a population which, having been subjected to pro-inflammatory cytokines in vivo, were rendered unresponsive to other stimulatory signals. Neither of these is a likely explanation for our results for several reasons. First, the pattern of pharmacologic inhibition of EIgG ingestion was identical for LAD PMN and unstimulated normal PMN (Fig. 3) . Ingestion by unstimulated normal PMN is unaffected by H7, a PKC inhibitor, but is inhibited by DiBcAMP, whereas phorbol ester-stimulated ingestion exhibits the opposite pattern of inhibition. If LAD PMN were upregulated in vivo, IgG-mediated phagocytosis by these PMN would be inhibited by H7 but resistant to the effects of DiBcAMP. In fact, the opposite was the case, demonstrating that LAD PMN use a molecular mechanism for ingestion equivalent to that used by resting, unstimulated, normal PMN.
In addition, other patients with recurrent infections exhibited normal activation for enhanced ingestion in vitro. We examined ingestion by PMN from patients with CGD, another genetic disease with a predisposition to recurrent bacterial infections. These patients represented a population which, like the LAD patients, were subject to chronic or recurrent infections, and the consequent generation of pro-inflammatory cytokines in vivo. Evidence for exposure of both LAD and CGD PMN to inflammatory signals in vivo was given by the variable presence of FcRI on these patients' PMN. Normal resting PMN express minimal amounts ofFcRI, but its expression can be induced in vitro by exposure ofPMN to interferon-y (8) and it can be detected on the surface ofPMN isolated from patients with infectious diseases (25) . CGD PMN (Fig. 6) phagocytic function is unlikely to be the consequence of exposure to inflammatory signals in vivo.
Ifthe failure to amplify ingestion in response to stimulation was a consequence of the absence of CD 1 b/CD 18 antigens, then treatment of normal PMN with monoclonal antibodies against CDI lb or CD1 8 might reproduce the LAD phenotype. Indeed, our data indicate that two MAb recognizing CD1 lb, OKM1 and OKM 10, inhibited the ability of normal PMN to augment ingestion in response to stimulation. Neither MAb affected unstimulated ingestion of EIgG (Fig. 6) . Thus OKM 1-and OKM10-treated normal PMN behaved in vitro like untreated LAD PMN. We asked if this was a property of the particular epitope recognized by these MAbs, because we and others have previously reported that some antibodies (such as IB4 and Mol) inhibit both unstimulated and stimulated ingestion (PKC independent and dependent) (15) (16) (17) . We postulated that the antibodies that inhibited both mechanisms of phagocytosis might actually induce the generation of a signal inhibitory to ingestion. The one signal we had determined previously to negatively affect unstimulated ingestion was cAMP, presumably working through PKA (3). When PMN were incubated with HA 1004 to inhibit PKA, MAb-IB4 treatment ofthose PMN no longer inhibited unstimulated ingestion of EIgG, whereas it retained the ability to inhibit PDBu-stimulated ingestion (Figs. 7 and 8 ). Because MAbs which recognize both CDl lb and CD1 8 could reproduce the LAD defect in vitro, and the defect was not a direct consequence ofthe in vivo exposure to inflammatory signals, our data indicate that the phagocytic defect in LAD is a direct consequence ofthe genetic abnormality.
In addition, we assessed the ability of Mo I and IB4 to augment intracellular levels of cAMP. Both Mo 1 and 1B4 augmented intracellular cAMP levels in response to stimulation with either immune complexes or FMLP (Fig. 9) . Even though most of our experiments were performed with IBMX-treated PMN, identical fold increases in net cAMP could be observed with untreated PMN at earlier time points. Therefore, the effects of Mo 1 and 1 B4 were not due to an artifact of the IBMX treatment. Our data do not prove directly that Mol and 1B4 inhibit unstimulated ingestion by activation of PKA. Conclusive proof will require elucidation of the mechanism by which cAMP inhibits unstimulated ingestion (i.e., phosphorylation of a specific protein) and showing identical effects of 1B4 and Mo 1. Recently published work indicates that 1B4 treatment can increase intracellular cAMP levels by preventing CDl lb/ CDl 8-dependent decreases in cAMP (27). It is possible that Mo 1 and 1B4 are working in our studies by a similar passive mechanism. Our data most closely parallel studies performed with anti-CD29 treatment of lymphocytes (28) . Increases in intracellular cAMP were observed upon MAb engagement of CD29, a related integrin , chain, expressed by lymphocytes, but only when the cells were co-stimulated with anti-CD3 (28) . Thus, stimulation of PMN with EIgG in the presence of either Mo 1 or 1B4 during the phagocytosis assay could result in local accumulations of cAMP with activation of PKA and generation ofa signal inhibitory for PKC-independent ingestion. The significance ofthis observation to other effects ofMol and 1B4 is unknown; however, it is interesting to speculate that antiCDl lb/CD 1 8 activation of PKA may explain some of the anti-inflammatory effects of the anti-,B chain antibodies in various pathological conditions (29, 30) . It is equally intriguing to speculate that ligand engagement of CDl lb/CD 1 8-bearing receptors could also stimulate cAMP accumulation, which may mediate via PKA some ofthe pleiotropic biological effects of this integrin family.
Because CDl lb/CD18-deficient PMN failed to demonstrate PKC-dependent phagocytic mechanisms, we investigated the ability of LAD PMN to activate PKC and to demonstrate other PKC-dependent functions. Using PKC translocation as an assay for PKC activation, we found that phorbol esters translocated PKC normally in LAD PMN (Fig. 4) . Thus, failure of PKC translocation could not explain the lack of phagocytic response of LAD PMN to phorbol esters. We also examined the ability of LAD PMN to generate a respiratory burst in response to phorbol esters, another cell function thought to be dependent on PKC activation. We found, as have others, that the generation of superoxide anion in response to phorbol ester stimulation as well as FMLP stimulation occurred but was quantitatively variable and without a consistent pattern of response. Some of the variability may represent differences in prior in vivo exposure to inflammatory signals. Nonetheless, these data showed that there was no general defect in PKC-dependent responses in LAD PMN. Therefore, the inability of LAD PMN to recruit phagocytic mechanisms dependent on PKC activation did not arise from a failure to activate PKC or from a general failure of PKC-dependent signal transduction.
In summary, our data demonstrate a specific defect in phagocytosis by LAD PMN. LAD PMN failed to amplify ingestion in response to stimulation by phorbol esters, cytokines including TNF-a, and RGD-containing adhesive proteins. These experiments indicate that a role for CDl lb/CD1 8 is essential for the phagocytic mechanism that predominates at inflammatory foci: i.e., ingestion stimulated by inflammatory signals. Our data indicate that the CDl lb/CD1 8-dependent mechanism of ingestion is also dependent on the activation of PKC. This suggests that PKC may play an important role in the regulation of CDl lb/CD 1 8 function, either by direct phosphorylation of the ,3 chain (31), or indirectly by phosphorylation of a cytoplasmic protein which alters the conformation or cytoskeletal association ofthe plasma membrane heterodimer. The importance of PKC-dependent and CDl lb/CD18-dependent phagocytic mechanisms to host defense is demonstrated by the fact that PMN from patients with diseases with a predisposition to serious recurrent infection (CGD, paroxysmal nocturnal hemoglobinuria, and LAD) fail to exhibit some or all of these mechanisms for the amplification ofingestion. The inability of phagocytes to normally upregulate their ingestion most likely contributes very significantly to the increased propensity to infection in patients with LAD. In support ofthis possibility is the clinical observation that LAD patients get significant bacterial pneumonias, despite apparently normal ingress of PMN to this site of infection (Dr. Anderson, personal observation).
